- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|No information available.|
|Summary of Clinical Use|
|Ixekizumab is approved for the treatment of psoriasis. Positive results from a Phase 2 study are reported in , and Phase 3 results are reviewed in . In March 2016, the US FDA approved ixekizumab for the treatment of moderate-to-severe plaque psoriasis. The EMA granted marketing authorisation in April 2016.
Phase 3 results following 60 weeks of treatment are reported in , showing longer term efficacy (with ~80% of patients seeing at least a 75% improvement in their skin symptoms at 60 weeks).
|Mechanism Of Action and Pharmacodynamic Effects|
|The IL-17 pathway is an established driver of psoriasis pathogenesis [7,9]. Ixekizumab effectively neutralises circulating IL-17A and reduces IL-17-induced pro-inflammatory signalling. This leads to an improvement in clinical disease symptoms. .|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)